Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
“We are pleased to report the results of our third quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “Our team remains diligent and focused on our plan to bring innovative topical therapies to dermatology and aesthetics practitioners and their patients. With our Phase 2b trial of SNA-120 underway, we are eager to advance SNA-125 into human trials within the first half of 2018.”
Sienna announced on Oct. 24, 2017, that the first patient had been dosed in the Company’s Phase 2b clinical trial of topical product candidate SNA-120 (pegcantratinib) in the treatment of pruritus, or itch, associated with psoriasis and in the treatment of psoriasis itself. SNA-120 is designed to selectively inhibit tropomyosin receptor kinase A, or TrkA, the high affinity receptor for nerve growth factor, or NGF, a known mediator of itch and neurogenic inflammation associated with psoriasis. Sienna expects to report top-line results in the first half of 2019.
On Oct. 12, 2017, the Company’s Chief Medical Officer, Dr. Paul Lizzul, highlighted Sienna’s Topical by Design™ platform as part of his presentation, “Addressing the Innovation Gap in Topical Dermatology Drug Development,” at the inaugural Dermatology Drug Development Summit in Boston. This summit brought together leading pharma, biotech and industry stakeholders to discuss how to transform and enhance the success of dermatology drug development activities. Dr. Lizzul was also a keynote panel member of the summit opening discussion, “A Therapeutic Revolution in Dermatology - Bridging the Gaps & Opportunities.”
Selected Financial Results
Total operating expenses for the three months ended Sept. 30, 2017, were approximately $14.3 million,